Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20/S21 men's GLP-1 obesity telemedicine at $50M+ ARR cashflow positive 24 months with $130K total raised; competing with Ro and Hims for men's obesity treatment at massive capital efficiency targeting 1M patients by end 2026.
Fella Health is a San Francisco-based men's obesity telemedicine platform — bootstrapped with minimal external funding ($130,000 seed from Y Combinator, Global Founders Capital, AngelList, and founders of Indeed, Curative, and Alan) — providing men with obesity and metabolic health challenges with a subscription-based direct-to-patient treatment program combining FDA-approved GLP-1 medications (semaglutide and tirzepatide), psychological strengthening, and behavioral interventions for significant weight loss and metabolic health improvement. Having achieved over $50 million in annual recurring revenue and cashflow positive operations for 24 months, with 76+ employees and a mission to serve 1 million men by end of 2026, Fella also operates Delilah Health for women through the same clinical model. Y Combinator W20/S21 backed.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.